Larry J Anderson

List of Publications by Year
in descending order

86 papers	12,386 citations	61984 43 h-index	58581 82 g-index
89 all docs	89 docs citations	89 times ranked	11883 citing authors

#	Article	IF	Citations
1	Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy. Journal of Allergy and Clinical Immunology, 2022, 149, 966-976.	2.9	11
2	The Challenge of Respiratory Syncytial Virus Human Challenge Studies. New England Journal of Medicine, 2022, 386, 696-697.	27.0	3
3	Exclusive breast-feeding, the early-life microbiome and immune response, and common childhood respiratory illnesses. Journal of Allergy and Clinical Immunology, 2022, 150, 612-621.	2.9	23
4	Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years. Frontiers in Immunology, 2022, 13, 826666.	4.8	16
5	Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination. Virology, 2022, 569, 44-55.	2.4	2
6	Nasopharyngeal Haemophilus and local immune response during infant respiratory syncytial virus infection. Journal of Allergy and Clinical Immunology, 2021, 147, 1097-1101.e6.	2.9	12
7	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. Journal of Immunological Methods, 2021, 488, 112900.	1.4	6
8	Detection of respiratory syncytial virus defective genomes in nasal secretions is associated with distinct clinical outcomes. Nature Microbiology, 2021, 6, 672-681.	13.3	35
9	CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Induction of Nucleolin and Dysregulation of Cilium-Related Genes. Journal of Virology, 2021, 95, .	3.4	14
10	Functional Features of the Respiratory Syncytial Virus G Protein. Viruses, 2021, 13, 1214.	3.3	21
11	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology, 2021, 559, 1-9.	2.4	29
12	Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0256482.	2.5	16
13	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiology Spectrum, 2021, 9, e0045821.	3.0	3
14	Metabolic Reprogramming of Nasal Airway Epithelial Cells Following Infant Respiratory Syncytial Virus Infection. Viruses, 2021, 13, 2055.	3.3	12
15	Performance evaluation of antibody tests for detecting infant respiratory syncytial virus infection. Journal of Medical Virology, 2021, 93, 3439-3445.	5.0	3
16	1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2021, 8, S752-S753.	0.9	0
17	1334. Outcomes Among Influenza and SARS-CoV-2 Infection in Hospitalized Adults Age â‰¥ 50 Years and with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2021, 8, S755-S755.	0.9	0
18	1340. The Burden of Influenza and Rhinovirus Among Hospitalized Adults Post the COVID-19 Pandemic. Open Forum Infectious Diseases, 2021, 8, S757-S758.	0.9	1

#	Article	IF	Citations
19	A Respiratory Syncytial Virus Attachment Gene Variant Associated with More Severe Disease in Infants Decreases Fusion Protein Expression, Which May Facilitate Immune Evasion. Journal of Virology, 2020, 95, .	3.4	8
20	Two RSV Platforms for G, F, or G+F Proteins VLPs. Viruses, 2020, 12, 906.	3.3	7
21	In vitro model for the assessment of human immune responses to subunit RSV vaccines. PLoS ONE, 2020, 15, e0229660.	2.5	6
22	Mutation of Respiratory Syncytial Virus G Proteinâ€™s CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. Vaccines, 2019, 7, 69.	4.4	15
23	Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. Frontiers in Immunology, 2019, 10, 1675.	4.8	39
24	2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). Open Forum Infectious Diseases, 2019, 6, S793-S794.	0.9	0
25	RSV Strains and Disease Severity. Journal of Infectious Diseases, 2019, 219, 514-516.	4.0	10
26	Sex-specific association between prenatal life stress exposure and infant pro-inflammatory cytokine levels during acute respiratory infection. Brain, Behavior, and Immunity, 2019, 76, 275-279.	4.1	3
27	Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. Cell Reports, 2018, 22, 2504-2517.	6.4	150
28	Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Research, 2018, 154, 149-157.	4.1	36
29	Nasopharyngeal Lactobacillus is associated with a reduced risk of childhood wheezing illnesses following acute respiratory syncytial virus infection in infancy. Journal of Allergy and Clinical Immunology, 2018, 142, 1447-1456.e9.	2.9	74
30	Using urine metabolomics to understand the pathogenesis of infant respiratory syncytial virus (RSV) infection and its role in childhood wheezing. Metabolomics, 2018, 14, 135.	3.0	28
31	The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. Viruses, 2018, 10, 446.	3.3	69
32	Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1064-1073.	5.6	56
33	A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. Viruses, 2018, 10, 38.	3.3	22
34	MUC5AC Levels Associated With Respiratory Syncytial Virus Disease Severity. Clinical Infectious Diseases, 2018, 67, 1441-1444.	5.8	9
35	Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy. Journal of Infectious Diseases, 2017, 215, 1102-1106.	4.0	68
36	Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. Virology, 2017, 512, 144-150.	2.4	7

#	Article	IF	Citations
37	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNÎ³ priming. Blood Advances, 2017, 1, 628-643.	5.2	43
38	The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection. Vaccines, 2017, 5, 16.	4.4	25
39	Seasonal Timing of Infant Bronchiolitis, Apnea and Sudden Unexplained Infant Death. PLoS ONE, 2016, 11, e0158521.	2.5	5
40	Differences in the Nasopharyngeal Microbiome During Acute Respiratory Tract Infection With Human Rhinovirus and Respiratory Syncytial Virus in Infancy. Journal of Infectious Diseases, 2016, 214, 1924-1928.	4.0	84
41	Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Scientific Reports, 2016, 6, 26311.	3.3	77
42	Nasopharyngeal Microbiome in Respiratory Syncytial Virus Resembles Profile Associated with Increased Childhood Asthma Risk. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1180-1183.	5.6	63
43	Detection of RSV Antibodies in Human Plasma by Enzyme Immunoassays. Methods in Molecular Biology, 2016, 1442, 41-52.	0.9	3
44	Secretory Expression and Purification of Respiratory Syncytial Virus G and F Proteins in Human Cells. Methods in Molecular Biology, 2016, 1442, 53-62.	0.9	0
45	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine, 2016, 34, 4843-4849.	3.8	49
46	Minimally Invasive Sampling Method Identifies Differences in Taxonomic Richness of Nasal Microbiomes in Young Infants Associated with Mode of Delivery. Microbial Ecology, 2016, 71, 233-242.	2.8	54
47	Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis. F1000Research, 2016, 5, 1920.	1.6	3
48	CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. Journal of General Virology, 2015, 96, 2543-2556.	2.9	110
49	Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). BMC Pulmonary Medicine, 2015, 15, 45.	2.0	45
50	An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology, 2015, 483, 117-125.	2.4	60
51	Human Rhinovirus Induced Cytokine/Chemokine Responses in Human Airway Epithelial and Immune Cells. PLoS ONE, 2014, 9, e114322.	2.5	46
52	Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice. Journal of Virology, 2014, 88, 10569-10583.	3.4	48
53	Respiratory syncytial virus vaccine development. Seminars in Immunology, 2013, 25, 160-171.	5.6	50
54	Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, 2013, 372, 391-404.	1.1	48

#	Article	IF	Citations
55	A Respiratory Syncytial Virus (RSV) Anti-G Protein F(abâ€²) ₂ Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice. Journal of Virology, 2013, 87, 10955-10967.	3.4	53
56	Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses. Journal of Virology, 2013, 87, 13466-13479.	3.4	82
57	Response to Rhinovirus Infection by Human Airway Epithelial Cells and Peripheral Blood Mononuclear Cells in an In Vitro Two-Chamber Tissue Culture System. PLoS ONE, 2013, 8, e66600.	2.5	35
58	Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. PLoS ONE, 2013, 8, e74905.	2.5	46
59	Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice. PLoS ONE, 2013, 8, e83075.	2.5	17
60	Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993â€“2008. Clinical Infectious Diseases, 2012, 54, 1427-1436.	5.8	475
61	Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997â€“2006. Pediatric Infectious Disease Journal, 2012, 31, 5-9.	2.0	286
62	Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice. PLoS ONE, 2012, 7, e51485.	2.5	37
63	Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. Journal of Virological Methods, 2011, 174, 144-149.	2.1	33
64	Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43. Journal of Virological Methods, 2011, 177, 100-106.	2.1	15
65	Application of TaqMan Low-Density Arrays for Simultaneous Detection of Multiple Respiratory Pathogens. Journal of Clinical Microbiology, 2011, 49, 2175-2182.	3.9	201
66	Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naiˆve and Formalin-Inactivated RSV-Immunized BALB/c Mice. Journal of Virology, 2010, 84, 9632-9636.	3.4	64
67	Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice. Journal of Virology, 2010, 84, 1148-1157.	3.4	87
68	Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients. Journal of Immunology, 2009, 183, 6338-6345.	0.8	87
69	Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(abâ€²)2 components mediates reduced pulmonary inflammation in mice. Journal of General Virology, 2009, 90, 1119-1123.	2.9	64
70	Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice. Journal of Infectious Diseases, 2009, 200, 439-447.	4.0	115
71	Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins. Vaccine Journal, 2007, 14, 331-333.	3.1	22
72	Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses. Journal of Immunology, 2006, 176, 1600-1608.	0.8	127

#	Article	IF	Citations
73	Real-Time Reverse Transcriptionâ€“Polymerase Chain Reaction Assay for SARS-associated Coronavirus. Emerging Infectious Diseases, 2004, 10, 311-316.	4.3	279
74	Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. Science, 2003, 300, 1394-1399.	12.6	2,238
75	The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P. Journal of Virology, 2003, 77, 6580-6584.	3.4	81
76	Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. JAMA - Journal of the American Medical Association, 2003, 289, 179.	7.4	3,197
77	Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. Journal of Virology, 2003, 77, 9831-9844.	3.4	109
78	Substantial variability in community respiratory syncytial virus season timing. Pediatric Infectious Disease Journal, 2003, 22, 857-863.	2.0	160
79	Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helperâ€“1 and T Helperâ€“2 Cytokines and CC Chemokine Messenger RNA. Journal of Infectious Diseases, 2002, 185, 1388-1394.	4.0	77
80	Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. Journal of Virology, 2001, 75, 10730-10737.	3.4	447
81	CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology, 2001, 2, 732-738.	14.5	380
82	Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology, 2000, 1, 398-401.	14.5	1,482
83	Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse. Journal of Virology, 2000, 74, 6227-6229.	3.4	89
84	Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice. Journal of Virology, 2000, 74, 1614-1622.	3.4	77
85	Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. Journal of Virology, 1999, 73, 7099-7107.	3.4	145
86	Protective Activity of a Human Respiratory Syncytial Virus Immune Globulin Prepared from Donors Screened by Microneutralization Assay. Journal of Infectious Diseases, 1992, 165, 456-463.	4.0	106